Published in final edited form as:

J Oral Rehabil. 2015 December ; 42(12): 956–966. doi:10.1111/joor.12324.

Perspectives on Next Steps in Classification of Orofacial Pain – Part 3: Biomarkers of Chronic Orofacial Pain – From Research to Clinic

Werner Ceusters^{*}, Cibeles Nasri-Heir^{**}, Deyaaeddin Alnaas^{**}, Brian E Cairns^{***}, Ambra Michelotti^{****}, and Richard Ohrbach^{*****}

^{*} Department of Biomedical Informatics, University at Buffalo, NY, USA

^{**} Rutgers School of Dental Medicine, Newark, NJ, USA

^{***} Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

^{****} Section of Orthodontics, School of Dentistry, University of Naples Federico II, Naples, Italy

^{*****} Department of Oral Diagnostic Sciences, University at Buffalo, NY, USA

Abstract

The purpose of this paper is to review the current status of biomarkers used in orofacial pain conditions. Specifically, we critically appraise their relative strengths and weaknesses for assessing mechanisms associated with the orofacial pain conditions and interpret that information in light of their current value for use in diagnosis. In the third section, we explore biomarkers through the perspective of ontological realism. We discuss ontological problems of biomarkers as currently widely conceptualized and implemented. This leads to recommendations for research practice aimed to a better understanding of the potential contribution that biomarkers might make to orofacial pain diagnosis and thereby fulfill our goal for an expanded multi-dimensional framework for orofacial pain conditions that would include a third axis.

Keywords

Chronic orofacial pain; temporomandibular disorders; pain; biomarkers; ontology; classification

1 INTRODUCTION

The Institute of Medicine (IOM) defines a biomarkers as “... characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes or responses to an intervention.” (1) Biomarkers whose relationship to disease is not clearly established are termed “investigative” (2). Investigative biomarkers can be

Correspondence to Richard Ohrbach, 355 Squire, University at Buffalo, Buffalo, NY 14214, Voice: +01-716-829-3590, FAX: +01-716-829-3554, ohrbach@buffalo.edu.

DISCLOSURES

The authors have no conflicts of interest to declare.

The views expressed in this publication are those of the authors and not necessarily those of the National Institute of Dental and Craniofacial Research in the USA.

developed to differentiate between being diseased and non-diseased (diagnostic), to assess the severity or extent of disease (burden of disease), to predict future onset of disease (prognostic), and/or to provide information about treatment effectiveness (efficacy of intervention) (2). Biomarkers are often used as surrogate endpoints, i.e. as a substitute for a clinical endpoint. For example, in blood pressure trials of antihypertensive drugs, drug-related decreased blood pressure (the biomarker) is associated with decreased risk of serious cardiovascular events.

The criteria for evaluation of potential biomarkers include these three key aspects and their respective parameters:

- **Analytical Validation** (sensitivity, specificity, reproducibility, ease of administration,)
- **Qualification** (evidence for association, study designs, e.g. case-control or prospective)
- **Utilization** (specific proposed use)

Blood glucose is a classic example of a biomarker used to diagnose and monitor diabetes. Glucose is easily and reliably measured, and well-defined normal and pathological ranges for blood glucose exist for the population. Blood glucose levels are used to monitor the effectiveness of therapy with insulin and oral hypoglycemic agents. The degree to which glucose concentrations are controlled in diabetic patients can be used to predict long-term consequences of disease progression.

The authors of this paper were invited by the International RDC/TMD Consortium Network for a symposium, held at the 2013 IADR General Session in Seattle, in order to review biomarkers related to the development of an orofacial pain classification system. The other two papers are focused on general principles of ontology (3), and psychosocial considerations related to an orofacial pain taxonomy (4). This paper will first discuss biomarkers, in the context of usage in an orofacial pain diagnostic and classification system, and then it will critically assess the various problems that affect such potential usage.

2 BIOMARKER CANDIDATES FOR OROFACIAL PAIN

Biomarkers for orofacial pain discussed in the present paper can be categorized by the method used to measure them: a) physiological (e.g., reflex responses, pressure pain thresholds, quantitative sensory testing); b) psychological or behavioral characteristics (e.g., dynamic pain psychophysical testing); c) radiological (computed tomography (CT), magnetic resonance imaging (MRI), functional MRI, positron emission tomography (PET); and d) molecular (small molecules (amino acids, prostaglandins, leukotrienes) and proteins (e.g. cytokines, COX, etc). Increasingly investigated biomarkers are genomic and transcriptomic in nature, but this is beyond the scope of the present paper. The following sections discuss the use and potential application of some of these biomarker candidates and applicable tests.

We have grouped potential craniofacial biomarkers into 3 categories, based on their method of acquisition as follows: direct physiological measures, biosamples, and imaging (5). Direct

physiological measures require the use of a stimulus that is typically nociceptive (e.g., pressure, thermal) but it may also be non-nociceptive (e.g., pressure, movement), and such measures assess the impact of the stimulus on a physiological (reflex) or behavioral response as the measurement. Molecules (metabolites, proteins, nucleic acids, etc) are assessed via a biosample (e.g. blood, saliva, cerebrospinal fluid, tissue biopsy) and the process of acquiring a sample may include a stimulus (for example, nociceptive) or sample acquisition may be with the organism at rest, and while a behavioral response by the individual may accompany the process of collecting the sample, such a response is not necessary nor is the response part of the measurement. Imaging includes magnetic resonance imaging (MRI) based techniques (diffusion tensor imaging, spectroscopy, volumetric MRI, functional MRI), X-rays including computed tomography scans, positron emission tomography, which reveal structural changes and can also provide information about local metabolic activity.

2.1 Direct Physiological Measures

Pressure pain threshold (PPT) is the minimum load required to cause a painful sensation from a specific tissue (e.g. skin, muscle, joint) and forms part of the compliment of tests employed in quantitative sensory testing (QST; discussed below). PPT can be easily measured in an office with an algometer. PPT can be used for diagnosis and to determine treatment efficacy, for example, by assessing pain sensitivity in the masticatory muscles and the temporomandibular joint of individuals with symptoms compatible with temporomandibular disorders (TMD). It has been suggested that PPT in the masseter muscle may be as good as palpation to recognize TMD-related pain (6). One advantage of PPT measurement data is that they are usually found to have good to excellent inter-examiner reliability (7). However, to use PPTs in this way would require that there be standardized, accepted instrumentation for measuring them, standardized units for reporting the load, specific criteria for PPT application (loading area, rate of stimulus application, sites to be tested, number of trials), and perhaps a determination of what other factors might significantly affect the PPT (menstrual cycles, diurnal cycle). Also to be determined are what constitute normal values in healthy individuals, and what values fall outside of the range of “normality” (8). Although substantially lower masticatory muscle PPT values have been found in large cohorts of TMD patients when compared with healthy controls (7) these differences have not always been detected in small group studies due to the variability inherent in PPT values (9, 10), reducing the diagnostic utility of this biomarker. It is unclear whether analgesic interventions alter both PPT and TMD symptoms in a related manner, and this question warrants further investigation.

The jaw-stretch reflex is a monosynaptic stretch reflex that can be evoked by rapid depression of the mandible. Jaw-stretch reflexes can be measured in an office but accurate measurement requires relatively complex equipment. Because some factors (e.g., EMG activity and jaw displacement) influence the amplitude of the reflex itself, while other factors (e.g. recording site) influence the amplitude of the registered measurement, standardized parameters for measuring jaw-stretch reflexes would need to be developed. While it is clear that experimental muscle pain alters the amplitude of the stretch reflex (11-14), it is not clear whether clinical pain, such as masticatory muscle pain associated with TMD, reliably modulates this reflex. In TMD patients with joint pain, injection of lidocaine

into the joint reduces the jaw-stretch reflex and ongoing pain (15). On the other hand, skeletal muscle relaxants have very little effect on enhancement of the reflex that can be produced by experimental masseter muscle pain (16). Thus, the jaw-stretch reflex may be more useful in assessing the integrity of the trigeminal sensory system, rather than as a biomarker of disease for TMD (15, 17-19).

Traditional quantitative sensory testing (QST) provides a powerful method of assessment for sensory functioning and for the effectiveness of different treatments (20). In this method, standardized noninvasive stimuli of different modalities are applied to measure the functionality of different nerve fiber populations. As an indication of response, the method relies on subjective verbal or non-verbal report (20), and the assessment of functioning is made through evaluation of sensory thresholds (detection and pain thresholds, pain tolerance, pain summation thresholds), supra-threshold intensity ratings (response-magnitude and stimulus-response relationships), and sensory mapping (20). The assumption is that the responses to various stimuli provide information about the functionality of the peripheral and central nervous systems.

Standardization is difficult to achieve with QST, as data from one assessment system cannot be easily compared to another. This discrepancy can be somewhat reduced by routinely using the same methods and devices, and by using the patient's contralateral side as a reference when possible (21). In order to maximize accuracy, QST analysis should assess sensitivity at a number of locations: the painful (affected area), contralateral and neighboring sites, and non-related sites. All tested locations should be methodically mapped and sensory alterations beyond the primary affected site may indicate systemic disease or centrally mediated conditions that will require further evaluation. A major limitation to standardization that is more difficult to overcome is that the test's accuracy relies on patient responses. The patient's response can be biased, influenced either by a time gap between experiencing the sensation and providing the response, or by a range of expectations specific to the patient. These biases can generally be controlled by more sophisticated but time-consuming psychophysical methods (stair case, etc.).

QST alone has no diagnostic power; however it can add an additional dimension to pain evaluation. Various clinical conditions and pathological processes may have a different, characteristic sensory signature. For example, severe nerve injury (partial or complete nerve transection) is typically characterized by immediate myelinated and unmyelinated nerve fibre hyposensitivity that will be represented by elevated detection thresholds of sensitivity to all modalities (22). Partial damage may be followed by either hypo or hypersensitivity accompanied by on-going neuropathic pain (23, 24). Another example is that early perineural inflammation may produce short lasting large myelinated nerve fibre hypersensitivity that is revealed clinically by reduced detection threshold in those fibres (25-30).

Employing QST can enable the practitioner to distinguish between allodynic conditions (i.e., where pain is caused due to a stimulus that normally would not evoke pain). In allodynia conditions, the pain threshold is reduced whereas the detection threshold can increase, decrease or remain unchanged. The interval between detection and pain thresholds, for

example, has been shown to have clinical significance in the assessment of centrally mediated pain conditions (31). Similarly, several types of hyperalgesic conditions can be defined as well. Heat hyperalgesia, for example, is related to thin unmyelinated nerve fibers while tactile hyperalgesia may suggest involvement of myelinated fibers.

A significant attempt to standardize QST was made by The German Research Network on Neuropathic Pain (32). The Network employed a systematic sequence of thermal and mechanical QST on patients suffering from various neuropathic pain conditions. The findings were categorized as gain and loss of sensation. Ninety two percent of the patients presented with at least one sensory abnormality, and a sensory profile was suggested for each neurological syndrome. However, combinations of gain and loss of sensations were found to exist across all the evaluated pain syndromes, thereby reducing diagnostic specificity. Nevertheless, there is preliminary evidence for alterations in the QST profiles of some TMD patients compared to healthy controls and chronic widespread (fibromyalgia) patients (33), suggesting that QST may be able to provide specific pain signatures that could be used to assist in the diagnosis of orofacial pain conditions. However, as mentioned earlier, this method alone has no diagnostic power. Guidelines for the assessment of orofacial somatosensory function in the clinical setting exist (20) but they are not yet standardized or validated; consequently, there is an ongoing effort to develop consistent approaches for assessment (34). These will be required for this technique to be evaluated as a potential biomarker of TMD and other orofacial pain conditions.

Dynamic pain psychophysical testing is part of a new generation of psychophysical testing that allows for the evaluation of modulatory processes. This method comes in addition to recognizing the pain perception obtained by static pain psychophysics of thresholds or supra-threshold magnitude evaluation, described above under QST. The technique relies on the fact that pain perception is the result of generated data from the periphery, which is transmitted centrally, and then modulated in the CNS before its arrival in the cortex for conscious perception. Therefore, the same type of external stimulus may evoke perceptions of different sorts among different people, depending on their central modulation processes and the situation they are in.

Two modulatory mechanisms are commonly tested in the laboratory or clinic. One is Temporal Summation (TS), the psychophysical correlate of “wind-up”, a process whereby repeated noxious stimulation results in progressively larger neuronal responses and reflects central sensitization; note that TS is often subsumed within the QST rubric. TS is thought to result from increased activation of N-methyl-D-aspartate (NMDA) receptors in response to sustained nociceptive input. The clinical manifestation of TS may be allodynia and hyperalgesia (35-37). TS is tested by application of a number of repeated nociceptive stimuli at a fixed interval. The increase in pain score is assessed at the end of the final stimulus. The second mechanism is Conditioned Pain Modulation (CPM), which is thought to be the human psychophysical equivalent of Diffuse Noxious Inhibitory Control (DNIC). CPM represents the endogenous analgesia system, where descending pathways induce modulatory effects on incoming painful stimuli. This phenomenon, at least partially, is opioid-mediated (38). Animal studies demonstrated the role of spinal noradrenaline (NA) and serotonin (5-

HT) in mediation of pain inhibition and CPM (39-44). CPM is tested in the lab using two remote noxious stimuli, where the first 'conditioning pain' inhibits the second 'test pain'.

In recent years many reports used TS or CPM to demonstrate altered pain modulation in chronic pain patients. Enhanced TS was found in chronic pain patients such as fibromyalgia (45-48), tension headache and musculoskeletal pain (49, 50), migraine (51), chronic low back pain (52), and Temporomandibular Disorders (TMD) (53-57). Similarly, a less-efficient CPM response was found in many of the idiopathic pain syndromes such as TMD (58), fibromyalgia (48, 59-61), tension headache (62) and Irritable Bowel Syndrome (63). Among healthy subjects, reduced pain-modulatory capacity was demonstrated in older subjects (64) and among females when compared with males (65). Less efficient CPM was found among patients with chronic post endodontic treatment pain as well (Nasri-Heir et al., unpublished data).

It has been suggested that dysregulation of the pain modulatory system can lead to the development of chronic pain disorders (66-69). Patients with altered pain modulation are more prone to develop post-operative (thoracotomy) chronic pain (70). Moreover, a recent study has shown that painful diabetic neuropathy patients with less efficient CPM benefit more from treatment with duloxetine (71) that has the potential to enhance the descending pain inhibition by inhibiting reuptake of spinal noradrenalin (NA) and serotonin (71-73).

The pain modulatory system can be activated by stimuli other than pain; isometric contraction and exercise have been shown to be strong descending pain inhibitory system motivators (74). A recent study demonstrated that subjects with high CPM induced by painful heat stimulus also exhibited high CPM induced by isometric contraction (Eliav et al, unpublished data). This may suggest common mechanisms or pathways for pain-induced and isometric muscle contraction-induced CPM.

2.2 Biosamples

Biomarkers from blood have been identified for many diseases, including the example of diabetes given earlier. There are reasonably good biomarkers of inflammation, but as yet it has been difficult to find a molecular biomarker of pain, let alone for a specific type of pain such as orofacial pain related to TMD. This is compounded by the finding of little evidence of gross pathological changes to the masticatory muscle tissues of TMD patients with myalgia (75). Despite the lack of gross pathology, microdialysis studies have recently found that interstitial glutamate concentrations are 2-4 times greater in the masseter muscle of myofascial TMD patients than in healthy controls (9). In an animal model, a similar 2-3 times elevation of interstitial glutamate concentrations over baseline in the masseter muscle is associated with excitation and mechanical sensitization of masseter muscle nociceptors (76). These findings could indicate that glutamate concentration in the masseter muscle reflects ongoing disease, and therefore could serve as a diagnostic biomarker. In addition to glutamate, studies employing microdialysis have demonstrated elevated levels of serotonin, leukotriene B4, lactate and pyruvate in localized myalgias, however, most of these results have come from studies on muscles other than masticatory muscle in patients who had chronic myofascial pain that was not diagnosed as a TMD (77).

Other molecular biomarkers of disease have been identified in the TMJ, including tumour necrosis factor (TNF) α , an inflammatory cytokine which is found at significantly higher concentrations in the TMJ synovial fluid of patients with evidence of joint damage (78, 79), although there is no correlation between pain and TNF α concentrations (80). Recently, blood levels of three other cytokines, monocyte chemotactic protein 1 (MCP-1), interleukin (IL) 1ra, and IL-8, have been shown to be expressed at higher levels in TMD patients compared to healthy controls and their pattern of expression appears to differentiate patients with wide spread pain from those with pain localized to the orofacial region (81). Specifically, MCP-1 and IL-1ra are selectively elevated in TMD patients with localized pain, while IL-8 is selectively elevated in TMD patients with widespread pain. MCP-1 is a pro-inflammatory cytokine released upon local inflammation and promotes the release of CGRP. IL-1ra is anti-inflammatory and blocks IL1 pathway mediating pain. IL-8 is pro-inflammatory and may also be elevated in fibromyalgia.

2.3 Imaging

Imaging techniques that have been employed to investigate central nervous system function in orofacial pain research include computed tomography scans, magnetic resonance imaging (MRI, functional MRI (fMRI) and positron emission tomography (PET) scans (82-85). Other magnetic resonance-based measures include diffusion tensor imaging, spectroscopy and volumetric imaging (86). In terms of central nervous system function, fMRI has been employed to identify cortical and subcortical regions that appear to be activated during painful experiences, although none of the structures activated are uniquely activated by pain (86). Thus, while no specific pattern of brain activation has yet been identified in individuals suffering from pain, several lines of evidence suggest that the insular cortex may be a critical site of pain integration (86). There is some evidence that cortical activation induced by innocuous stimulation differs under conditions of ongoing orofacial pain. Through the use of fMRI it has been found that experimental pain from the facial skin or masseter muscles causes bilateral activation of the ventroposterior thalamus (VPM), whereas, innocuous stimulation (brushing the face) results only in activation of the contralateral VPM. This suggests that fMRI signals from the thalamus may prove useful as a means to differentiate between noxious and innocuous pain input from the face (84). Cortical activation in response to low frequency vibration of the index finger in TMD patients appeared to be increased in several key regions when compared to healthy controls, but no major difference in the pattern of activation was identified (83). At present, fMRI patterns cannot be used as a biological marker of orofacial pain.

For imaging of masticatory muscles or TMJ, there are comparatively fewer options (87-89). One very interesting technique that has been recently applied to study TMD patients is MRI diffusion tensor imaging/fractional anisotropy to assess white matter in the central roots of the trigeminal nerve (90). This technique employed fractional anisotropy, a measure of relative diffusion in 3 dimensions. It is thought that decreases in fractional anisotropy reflect nerve pathology such as decreased fiber density, axonal diameter or myelination. TMD patients had significantly lower levels of fractional anisotropy in the central root of the trigeminal nerve, which may indicate that this technique has identified a pathological change in the trigeminal nerve associated with TMD-related pain. The degree of fractional

anisotropy is associated with disease duration, making this potential biomarker a candidate for both diagnosis and disease burden, if these findings can be replicated in larger patient cohorts. Unfortunately, MRI is expensive and the availability of MRI machines varies greatly in different countries (78, 88, 91).

3 Ontological perspectives on biomarkers and diagnostic classifications for orofacial pain disorders

3.1 The standard definition for ‘biomarker’ violates ontological principles

For the notion of a biomarker to play a prominent role in diagnostic classifications, for instance in the formulation of diagnostic criteria, there must be a uniform understanding amongst developers of such classifications about what biomarkers precisely are and whether all entities to which the term ‘biomarker’ is assigned form a uniform group. For a group of entities to be uniform, all and only its members must exhibit a certain combination of characteristics and this is so irrespective of whether science has advanced enough to discover this unique combination of characteristics and whether an appropriate terminology has been developed to report on these characteristics adequately. This understanding must thus also include in what way biomarkers are distinct from other entities on the side of the patient such as signs, symptoms, and diagnostic tests that are applied to them – all entities which are already standardly referred to in the formulation of diagnostic classes and corresponding criteria. And finally, a similar understanding must be established for each of the various sorts of biomarkers as, for instance, suggested by terms used in previous sections such as ‘investigative biomarkers’, ‘prognostic biomarkers’, ‘radiologic biomarkers’, and so forth.

Unfortunately, the IOM has not provided a definition for ‘biomarker’ which is such as to denote all and only entities from some uniform group. The definition exhibits, for example, the conflation often encountered in medical discourse between entities on the side of the organism – in the case of healthcare: human beings – and the *evidence* for the existence of such entities (92). This and other conflations are widespread, and it is thus no surprise to find examples thereof in the IOM’s report on biomarkers, for instance in ‘Cholesterol and blood sugar levels are biomarkers, as are blood pressure, enzyme levels, measurements of tumor size from MRI or CT, and the biochemical and genetic variations observed in age-related macular degeneration.’ (1)[p2] where characteristics on the side of the patient are conflated with measurements of these characteristics. Moreover, it is even unclear whether by ‘measurements’ is meant either (a) the processes of measuring an entity on the side of the patient or (b) the data – usually expressed as values of some sort – obtained through such a process of measuring. In (1)[p18], the need is expressed ‘...to develop a transparent process for creating well-defined consensus standards and guidelines for biomarker development, validation, qualification, and use [bold emphasis added] to reduce the uncertainty in the process of development and adoption.’ This would restrict biomarkers to be measuring processes and/or devices to assist in such processes as it is hard to fathom that what is proposed to be developed here are blood sugar levels and tumor sizes. But that then, in turn, cannot be lined up with the IOM’s definition for biomarker which is stated to be something that is (a) objectively measured – surely, the idea is not that what is measured would be the

measuring process of, for instance, blood glucose itself – and (b) an indicator for normal, pathological or response to treatment processes – clearly, the mere performance of some test is itself not an indication at all of what is going on in the patient, rather an indication of what is going on in the mind of the clinician as he is trying to find out what is going on in the patient.

That the terminology around biomarkers is inconsistent – a problem the IOM recognizes in its own report (1)[p22] but unfortunately is contributing to rather than solving it – does not mean that the ideas behind it don't have value. But it does mean that the terminology needs to be rendered unambiguous and anchored in an ontology which recognizes all types of entities to be referred to in standards and guidelines for biomarker development, validation, qualification, and use.

3.2 Biomarkers under the perspective of the Ontology of General Medical Science (OGMS)

Ceusters and Smith have recently proposed an ontological realism-based account for biomarkers (93). This account renders IOM's view of biomarkers coherent under the following assumptions: (1) that the IOM intended biomarkers to be entities on the side of the patient, and not (for example) processes on the part of the clinician or data obtained through such processes including what can be seen or measured for example in radiographic images; (2) that in requiring that biomarkers be 'objectively measured and evaluated' the IOM had in mind not that an entity becomes a biomarker after and because it has been measured and evaluated, but rather that it was a biomarker already prior to observation because of certain properties it has intrinsically; and (3) that the logical disjunction expressed by the 'or' in the list of processes for which the IOM definition asserts biomarkers to be an indicator has to be interpreted as an exclusive or (XOR). Thus they assume that the IOM would not accept as biomarker some entity "e" from which it cannot be determined whether "e" is the result of a normal process or of a pathological process, and so forth. Under these assumptions, it is possible to interpret the vague term 'characteristic' in the IOM definition as denoting that what is intended by the OGMS term 'bodily feature' (92).

Entities that qualify as bodily features are instances of one or other of the following three disjoint types: (1) physical bodily components (nerve cells, nociceptors, neurotransmitters, etc.) and components in the interior or on the surface of the body (pathogens, toxins, microbiome, ...); (2) bodily qualities such as cytokine concentrations; and (3) bodily processes in which physical components participate, irrespective of them being normal (e.g., neurotransmission and concordant pain sensation), pathological (e.g., phantom pain), or induced through interventions.

4 CONCLUSION

4.1 Uses of Biomarkers for Orofacial Pain

Biomarkers are needed to serve as diagnostic, burden of disease, prognostic or efficacy of intervention tools for temporomandibular disorders and other orofacial disorders causing pain. At present, however, there are no validated biomarkers of orofacial pain. An ideal biomarker needs to be easily and reliably measured either by a trained clinician in the office

or by a laboratory. Methodologies that provide or could provide fingerprint or signature type information, such as genetic or molecular profiling, QST or MRI based techniques or combinations of various techniques may define the unique pathology associated with orofacial conditions. However, these techniques are, at the moment, still time consuming, complicated, and expensive, and consequently their value as biomarkers will require the development of standardized and feasible clinical protocols as well as strong evidence for their diagnostic utility before they will be accepted into the mainstream of clinical assessment of orofacial pain. Given these constraints, there is a need to continue to evaluate simple biomarkers of orofacial pain such as physiological and molecular biomarkers.

4.2 Recommendations for ontology-based representation of biomarkers in diagnostic classifications and related criteria for orofacial pain

Both research aiming at the discovery of suitable biomarkers for orofacial pain and the adequate use thereof to build diagnostic classifications will benefit from the advantages ontology has to offer. An initial goal will be to clean up the terminology around biomarkers, the scope of which is much broader than only the domain of pain research. If this is not immediately feasible for biomedicine in general, then at least pain researchers could get a competitive advantage by implementing a few simple steps.

A good start would be to develop on the basis of the literature an inventory of biomarker candidates relevant for pain research and subsequent application for diagnostics. This inventory should include, for each biomarker, a number of essential information elements. One element is the type of bodily feature the biomarker is an instance of; the most generic and minimum allowed types, in terms of the OGMS, are physical component, bodily process, and bodily quality. If the biomarker is determined to be a physical component, then further subtyping should be documented using ontologies accepted in the Open Biomedical Ontologies Foundry (94) or candidate ontologies thereof; examples are the Foundational Model of Anatomy (95) for any bodily component down to individual cells, the Cellular Component taxonomy of the Gene Ontology (96), the Protein Ontology (97), and so forth.

If the biomarker is a bodily process, good candidate ontologies for clarifying the terminologies are the Biological Process and Molecular Function taxonomies of the Gene Ontology. Since bodily processes always depend on at least one bodily component, it should for such a biomarker also be indicated which bodily components it depends on, using one of the ontologies just mentioned. If that is not documented in the ontology used to type the biomarker, it should be added to the inventory of biomarker candidates.

If the biomarker is a bodily quality, a good ontology for further subtyping is the Phenotypic Quality Ontology (PATO) (98). As with processes, the biomarker candidate inventory should further contain information about what bodily component this biomarker is a quality of.

The second sort of information the inventory should contain is the type of investigation used in the cited literature source to determine the biomarker being documented. A candidate ontology for this is the Ontology of Biomedical Investigations (OBI) (99). Since various

types of assays can be used to measure the same biomarker, each biomarker might need several distinct measurement-related entries.

The third piece of information is, in case of an inventory aimed towards diagnostic classification development, where the biomarker is believed to be an indicator of the underlying pathology. This information is typically available as a diagnosis.

Acknowledgements

The work described is funded in part by grant 1R01-DE021917-01A1 (W. Ceusters and R. Ohrbach) from the National Institute of Dental and Craniofacial Research.

The authors would like to acknowledge and thank Dr Eli Eliav for his helpful critique of the manuscript.

References

1. Micheel, CM.; Ball, JR., editors. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. The National Academies Press; Washington, D.C.: 2010. p. 314
2. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. *Osteoarthritis Cartilage*. 2006; 14:723–7. [PubMed: 16733093]
3. Ceusters W, Benoliel R, Durham J, Raphael KG, Michelotti A, Ohrbach R. Perspectives on next steps in classification of orofacial pain -- Part 1: Role of ontology. *Journal of Oral Rehabilitation*. in review.
4. Durham J, Raphael KG, Benoliel R, Ceusters W, Michelotti A, Ohrbach R. Perspectives on next steps in classification of orofacial pain -- Part 2: Role of psychosocial factors. *Journal of Oral Rehabilitation*. in review.
5. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. *Circulation*. 2006; 113:2335–62. [PubMed: 16702488]
6. Visscher CM, Lobbezoo F, Naeije M. Comparison of algometry and palpation in the recognition of temporomandibular disorder pain complaints. *J Orofac Pain*. 2004; 18:214–9. [PubMed: 15509000]
7. Greenspan JD, Slade GD, Bair E, Dubner R, Fillingim RB, Ohrbach R, et al. Pain sensitivity risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case control study. *J Pain*. 2011; 12:T61–T74. [PubMed: 22074753]
8. Ishiura K, Kimura K, Tanaka M, Tanaka J, Tosa J, Kawazoe T. Relationship of pressure pain thresholds between the masticatory muscles and styloid process. Part 2. Healthy subjects and patients with temporomandibular disorders. *Nihon Hotetsu Shika Gakkai Zasshi*. 2008; 52:381–7. [PubMed: 18678972]
9. Castrillon EE, Ernberg M, Cairns BE, Wang K, Sessle BJ, Arendt-Nielsen L, et al. Interstitial glutamate concentration is elevated in the masseter muscle of myofascial temporomandibular disorder patients. *J Orofac Pain*. 2010; 24:350–60. [PubMed: 21197506]
10. Gomes MB, Guimarães JP, Guimarães FC, Neves AC. Palpation and pressure pain threshold: reliability and validity in patients with temporomandibular disorders. *Cranio*. 2008; 26:202–10. [PubMed: 18686497]
11. Wang K, Arendt-Nielsen L, Svensson P. Excitatory actions of experimental muscle pain on early and late components of human jaw stretch reflexes. *Arch Oral Biol*. 2001; 46:433–42. [PubMed: 11286808]
12. Wang K, Svensson P. Influence of methodological parameters on human jaw-stretch reflexes. *Eur J Oral Sci*. 2001; 109:86–94. [PubMed: 11347661]
13. Wang K, Svensson P, Arendt-Nielsen L. Effect of tonic muscle pain on short-latency jaw stretch reflexes in humans. *Pain*. 2000; 88:189–97. [PubMed: 11050374]

14. Cairns BE, Wang K, Hu JW, Sessle BJ, Arendt-Nielsen L, Svensson P. The effect of glutamate-evoked masseter muscle pain on the human jaw-stretch reflex differs in men and women. *J Orofac Pain*. 2003; 17:317–25. [PubMed: 14737876]
15. Wang K, Arendt-Nielsen L, Jensen TS, Svensson P. Reduction of clinical temporomandibular joint pain is associated with a reduction of the jaw-stretch reflex. *J Orofac Pain*. 2004; 18:33–40. [PubMed: 15022534]
16. Svensson P, Wang K, Arendt-Nielsen L. Effect of muscle relaxants on experimental jaw-muscle pain and jaw-stretch reflexes: a double-blind and placebo-controlled trial. *Eur J Pain*. 2003; 7:449–56. [PubMed: 12935797]
17. van Selms MK, Wang K, Lobbezoo F, Svensson P, Arendt-Nielsen L. Effects of masticatory muscle fatigue without and with experimental pain on jaw-stretch reflexes in healthy men and women. *Clin Neurophysiol*. 2005; 116:1415–23. M. N. [PubMed: 15978504]
18. Wang K, Sessle BJ, Svensson P, Arendt-Nielsen L. Glutamate evoked neck and jaw muscle pain facilitate the human jaw stretch reflex. *Clin Neurophysiol*. 2004; 115:1288–95. [PubMed: 15134695]
19. Truini A, Romaniello A, Svensson P, Galeotti F, Graven-Nielsen T, Wang K, et al. Experimental skin pain and muscle pain induce distinct changes in human trigeminal motoneuronal excitability. *Exp Brain Res*. 2006; 174:622–9. [PubMed: 16733707]
20. Svensson P, Baad-Hansen L, Pigg M, List T, Eliav E, Ettlin D, et al. Guidelines and recommendations for assessment of somatosensory function in oro-facial pain conditions - a taskforce report. *J Oral Rehabil*. 2011; 38:366–94. [PubMed: 21241350]
21. Kemler MA, Schouten HJ, Gracely RH. Diagnosing sensory abnormalities with either normal values or values from contralateral skin: comparison of two approaches in complex regional pain syndrome I. *Anesthesiology*. 2000; 93(3):718–27. [PubMed: 10969305]
22. Dao TT, Mellor A. Sensory disturbances associated with implant surgery. *Int J Prosthodont*. 1998; 11(5):462–9. [PubMed: 9922738]
23. Benoliel R, Eliav E, Iadarola MJ. Neuropeptide Y in trigeminal ganglion following chronic constriction injury of the rat infraorbital nerve: is there correlation to somatosensory parameters? *Pain*. 2001; 91(1-2):111–21. [PubMed: 11240083]
24. Benoliel R, Wilensky A, Tal M, Eliav E. Application of a pro-inflammatory agent to the orbital portion of the rat infraorbital nerve induces changes indicative of ongoing trigeminal pain. *Pain*. 2002; 99(3):567–78. [PubMed: 12406533]
25. Chacur M, Milligan ED, Gazda LS, Armstrong C, Wang H, Tracey KJ, et al. A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. *Pain*. 2001; 94(3):231–44. [PubMed: 11731060]
26. Gazda LS, Milligan ED, Hansen MK, Twining CM, Poulos NM, Chacur M, et al. Sciatic inflammatory neuritis (SIN): behavioral allodynia is paralleled by peri-sciatic proinflammatory cytokine and superoxide production. *J Peripher Nerv Syst*. 2001; 6(3):111–29. [PubMed: 11817330]
27. Eliav E, Benoliel R, Tal M. Inflammation with no axonal damage of the rat saphenous nerve trunk induces ectopic discharge and mechanosensitivity in myelinated axons. *Neurosci Lett*. 2001; 311(1):49–52. [PubMed: 11585565]
28. Eliav E, Gracely RH. Sensory changes in the territory of the lingual and inferior alveolar nerves following lower third molar extraction. *Pain*. 1998; 77(2):191–9. [PubMed: 9766837]
29. Eliav E, Herzberg U, Ruda MA, Bennett GJ. Neuropathic pain from an experimental neuritis of the rat sciatic nerve. *Pain*. 1999; 83(2):169–82. [PubMed: 10534588]
30. Eliav E, Teich S, Benoliel R, Nahlieli O, Lewkowicz AA, Baruchin A, et al. Large myelinated nerve fiber hypersensitivity in oral malignancy. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2002; 94(1):45–50. [PubMed: 12193892]
31. Sang CN, Max MB, Gracely RH. Stability and reliability of detection thresholds for human A-Beta and A-delta sensory afferents determined by cutaneous electrical stimulation. *J Pain Symptom Manage*. 2003; 25(1):64–73. [PubMed: 12565190]

32. Maier C, Baron R, Tolle TR, Binder A, Birbaumer N, Birklein F, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. *Pain*. 2010; 150(3):439–50. [PubMed: 20627413]
33. Pfau DB, Rolke R, Nickel R, Treede RD, Daublaender M. Somatosensory profiles in subgroups of patients with myogenic temporomandibular disorders and Fibromyalgia Syndrome. *Pain*. 2009; 147:72–83. [PubMed: 19767146]
34. Porporatti AL, Costa YM, Stuginski B, Bonjardim LR, Conti PC, Svensson P. Quantitative methods for somatosensory evaluation in atypical odontalgia. *Braz Oral Res*. 2015; 29(1) J. Online 1–7.
35. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. *Pain*. 1991; 44(3):293–9. [PubMed: 1828878]
36. Arendt-Nielsen L, Petersen-Felix S, Fischer M, Bak P, Bjerring P, Zbinden AM. The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. *Anesth Analg*. 1995; 81(1):63–8. [PubMed: 7598284]
37. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. *Eur J Pain*. 2000; 4(1):5–15. [PubMed: 10833550]
38. Yaksh TL, Elde RP. Factors governing release of methionine enkephalin-like immunoreactivity from mesencephalon and spinal cord of the cat in vivo. *J Neurophysiol*. 1981; 46(5):1056–75. [PubMed: 7299446]
39. Yaksh TL, Wilson PR, Kaiko RF, Inturrisi CE. Analgesia produced by a spinal action of morphine and effects upon parturition in the rat. *Anesthesiology*. 1979; 51(5):386–92. [PubMed: 582883]
40. Yaksh TL, Wilson PR. Spinal serotonin terminal system mediates antinociception. *J Pharmacol Exp Ther*. 1979; 208(3):446–53. [PubMed: 581884]
41. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). *Brain Res*. 1982; 236(2): 329–37. [PubMed: 6978166]
42. Lu Y, Perl ER. Selective action of noradrenaline and serotonin on neurones of the spinal superficial dorsal horn in the rat. *J Physiol*. 2007; 582:127–36. Pt 1. [PubMed: 17463043]
43. Pedersen LH, Scheel-Kruger J, Blackburn-Munro G. Amygdala GABA-A receptor involvement in mediating sensory-discriminative and affective-motivational pain responses in a rat model of peripheral nerve injury. *Pain*. 2007; 127(1-2):17–26. [PubMed: 16965855]
44. Pedersen LH, Nielsen AN, Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. *Psychopharmacology (Berl)*. 2005; 182(4):551–61. [PubMed: 16133135]
45. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. *Pain*. 2000; 85(3):483–91. [PubMed: 10781923]
46. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. *Pain*. 2001; 91(1-2): 165–75. [PubMed: 11240089]
47. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. *Pain*. 2002; 99(1-2): 49–59. [PubMed: 12237183]
48. Staud R, Robinson ME, Vierck CJ Jr, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. *Pain*. 2003; 101(1-2):167–74. [PubMed: 12507711]
49. Kleinbohl D, Holz R, Moltner A, Rommel C, Weber C, Osswald PM. Psychophysical measures of sensitization to tonic heat discriminate chronic pain patients. *Pain*. 1999; 81(1-2):35–43. [PubMed: 10353491]
50. Ashina S, Bendtsen L, Ashina M, Magerl W, Jensen R. Generalized hyperalgesia in patients with chronic tension-type headache. *Cephalalgia*. 2006; 26(8):940–8. [PubMed: 16886930]

51. Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky D. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. *Pain*. 2003; 104(3):693–700. [PubMed: 12927642]
52. Kleinbohl D, Gortelmeyer R, Bender HJ, Holzl R. Amantadine sulfate reduces experimental sensitization and pain in chronic back pain patients. *Anesth Analg*. 2006; 102(3):840–7. [PubMed: 16492838]
53. Sarlani E, Greenspan JD. Why look in the brain for answers to temporomandibular disorder pain? *Cells Tissues Organs*. 2005; 180(1):69–75. [PubMed: 16088135]
54. Maixner W, Fillingim R, Sigurdsson A, Kincaid S, Silva S. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain: evidence for altered temporal summation of pain. *Pain*. 1998; 76(1-2):71–81. [PubMed: 9696460]
55. Sarlani E, Grace EG, Reynolds MA, Greenspan JD. Sex differences in temporal summation of pain and aftersensations following repetitive noxious mechanical stimulation. *Pain*. 2004; 109(1-2): 115–23. [PubMed: 15082133]
56. Sarlani E, Grace EG, Reynolds MA, Greenspan JD. Evidence for up-regulated central nociceptive processing in patients with masticatory myofascial pain. *J Orofac Pain*. 2004; 18(1):41–55. [PubMed: 15029872]
57. Raphael KG, Janal MN, Anathan S, Cook DB, Staud R. Temporal summation of heat pain in temporomandibular disorder patients. *J Orofac Pain*. 2009; 23(1):54–64. [PubMed: 19264036]
58. Maixner W, Fillingim R, Booker D, Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. *Pain*. 1995; 63(3):341–51. [PubMed: 8719535]
59. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. *Pain*. 2005; 114(1-2):295–302. [PubMed: 15733656]
60. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. *Clin J Pain*. 1997; 13(3):189–96. [PubMed: 9303250]
61. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. *Pain*. 1997; 70(1):41–51. [PubMed: 9106808]
62. Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache. *Pain*. 2005; 118(1-2):215–23. [PubMed: 1620520]
63. King CD, Wong F, Currie T, Mauderli AP, Fillingim RB, Riley JL 3rd. Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder. *Pain*. 2009; 143(3):172–8. [PubMed: 19278784]
64. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. *Pain*. 2003; 101(1-2):155–65. [PubMed: 12507710]
65. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. *J Pain*. 2009; 10(5):447–85. [PubMed: 19411059]
66. Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse noxious inhibitory control (DNIC)-like effect in humans. *Pain*. 2009; 144(1-2):16–9. [PubMed: 19359095]
67. van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a model of endogenous pain modulation in clinical pain syndromes. *The journal of pain : official journal of the American Pain Society*. 2010; 11(5):408–19. [PubMed: 20075013]
68. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. *Curr Opin Anaesthesiol*. 2010; 23(5):611–5. [PubMed: 20543676]
69. Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. *Expert review of neurotherapeutics*. 2012; 12(5):577–85. [PubMed: 22550986]
70. Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, et al. Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. *Pain*. 2008; 138(1):22–8. [PubMed: 18079062]

71. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. *Pain*. 2012; 153(6):1193–8. [PubMed: 22480803]
72. Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. *Vasc Health Risk Manag*. 2007; 3(6):833–44. [PubMed: 18200804]
73. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. *J Pharmacol Exp Ther*. 2004; 311(2):576–84. [PubMed: 15254142]
74. Kosek E, Lundberg L. Segmental and plurisegmental modulation of pressure pain thresholds during static muscle contractions in healthy individuals. *Eur J Pain*. 2003; 7(3):251–8. [PubMed: 12725848]
75. Brooks SL, Westesson PL, Eriksson L, Hansson LG, Barsotti JB. Prevalence of osseous changes in the temporomandibular joint of asymptomatic persons without internal derangement. *Oral Surg Oral Med Oral Pathol Oral Radiol Endo*. 1992; 73:118–22.
76. Cairns BE, Dong XD, Mann MK, Svensson P, Sessle BJ, Arendt-Nielsen L, et al. Systemic administration of monosodium glutamate elevates intramuscular glutamate levels and sensitizes rat masseter muscle afferent fibers. *Pain*. 2007; 132:33–41. [PubMed: 17335976]
77. Gerdle B, Larsson B, Forsberg F, Ghafouri N, Karlsson L, Stenstrom N, et al. Chronic widespread pain: Increased glutamate and lactate concentrations in the trapezius muscle and plasma. *Clin J Pain*. 2014; 30:409–20. [PubMed: 23887335]
78. Kaneyama K, Segami N, Yoshimura H, Honjo M, Demura N. Increased levels of soluble cytokine receptors in the synovial fluid of temporomandibular joint disorders in relation to joint effusion on magnetic resonance images. *J Oral Maxillofac Surg*. 2010; 68:1088–93. [PubMed: 20149511]
79. Shafer DM, Assael L, White LB, Rossomando EF. Tumor necrosis factor- α as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. *J Oral Maxillofac Surg*. 1994; 52:786–91. [PubMed: 8040729]
80. Lee JK, Cho YS, Song SI. Relationship of synovial tumor necrosis factor α and interleukin 6 to temporomandibular disorder. *J Oral Maxillofac Surg*. 2010; 68:1064–8. [PubMed: 20031289]
81. Slade GD, Conrad MS, Diatchenko L, Rashid NU, Zhong S, Smith S, et al. Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. *Pain*. 2011; 152:2802–12. [PubMed: 22000099]
82. Weissman-Fogel I, Moayed M, Tenenbaum HC, Goldberg MB, Freeman BV, Davis KD. Abnormal cortical activity in patients with temporomandibular disorder evoked by cognitive and emotional tasks. 2011; 152:384–96.
83. Nebel MB, Folger S, Tommerdahl M, Hollins M, McGlone F, Essick G. Temporomandibular disorder modifies cortical response to tactile stimulation. *J Pain*. 2010; 11:1083–94. [PubMed: 20462805]
84. Nash PG, Macefield VG, Klineberg IJ, Gustin SM, Murray GM, Henderson LA. Bilateral activation of the trigeminothalamic tract by acute orofacial cutaneous and muscle pain in humans. *Pain*. 2010; 151:384–93. [PubMed: 20732744]
85. Kupers RC, Svensson P, Jensen TS. Central representation of muscle pain and mechanical hyperesthesia in the orofacial region: a positron emission tomography study. *Pain*. 2004; 108:284–93. [PubMed: 15030948]
86. Lee M, Tracey I. Imaging pain: a potent means for investigating pain mechanisms in patients. *British Journal of Anaesthesia*. 2013; 111(1):64–72. [PubMed: 23794647]
87. Manfredini D, Guarda-Nardini L. Ultrasonography of the temporomandibular joint: a literature review. *Int J Oral Maxillofac Surg*. 2009; 38:1229–36. [PubMed: 19700262]
88. Tomas X, Pomes J, Berenguer J, Quinto L, Nicolau C, Mercader JM, et al. MR imaging of temporomandibular joint dysfunction: a pictorial review. *Radiographics*. 2006; 26:765–81. [PubMed: 16702453]
89. Moen K, Hellem S, Geitung JT, Skartveit L. A practical approach to interpretation of MRI of the temporomandibular joint. *Acta Radiol*. 2010; 51:1021–7. [PubMed: 20942733]

90. Moayed M, Weissman-Fogel I, Salomons TV, Crawley AP, Goldberg MB, Freeman BV, et al. White matter brain and trigeminal nerve abnormalities in temporomandibular disorder. *Pain*. 2012; 153:1467–77. [PubMed: 22647428]
91. Bouloux GF. Temporomandibular joint pain and synovial fluid analysis: a review of the literature. *J Oral Maxillofac Surg*. 2009; 67:2497–504. [PubMed: 19837323]
92. Scheuermann, RH.; Ceusters, W.; Smith, B. Toward an Ontological Treatment of Disease and Diagnosis. Proceedings of the 2009 AMIA Summit on Translational Bioinformatics; San Francisco, California. March 15-17, 2009; 2009. p. 116-20. American Medical Informatics Association
93. Ceusters W, Smith B. Biomarkers in the Ontology for General Medical Science. *Medical Informatics Europe 2015 (MIE 2015)*. May 27-29.2015 Madrid, Spain2015. p. (accepted).
94. Smith B, Ashburner M, Ceusters W, Goldberg L, Mungall C, Shah N, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. *Nature Biotechnology*. 2007; 25:1251–5.
95. Rosse, C, Jr. The Foundational Model of Anatomy Ontology. In: Burger, A.; Davidson, D.; Baldock, R., editors. *Anatomy Ontologies for Bioinformatics: Principles and Practice*. Springer; London: 2007. p. 59-117.MJ
96. Huntley RP, Sawford T, Martin MJ, O'Donovan C. Understanding how and why the Gene Ontology and its annotations evolve: the GO within UniProt. *GigaScience*. 2014; 3(1):4. [PubMed: 24641996]
97. Natale DA, Arighi CN, Blake JA, Bult CJ, Christie KR, Cowart J, et al. Protein Ontology: a controlled structured network of protein entities. *Nucleic acids research*. 2014; 42(Database issue):D415–21. [PubMed: 24270789]
98. Gkoutos, GV.; Mungall, C.; Dolken, S.; Ashburner, M.; Lewis, S.; Hancock, J., et al. Entity/quality-based logical definitions for the human skeletal phenome using PATO. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference; 2009. p. 7069-72.
99. Vita R, Overton JA, Greenbaum JA, Sette A, consortium OBI. Peters B. Query enhancement through the practical application of ontology: the IEDB and OBI. *Journal of biomedical semantics*. 2013; 4(Suppl 1):S6. [PubMed: 23734660]